CA2308453A1 - Method of reducing craving in mammals - Google Patents

Method of reducing craving in mammals Download PDF

Info

Publication number
CA2308453A1
CA2308453A1 CA002308453A CA2308453A CA2308453A1 CA 2308453 A1 CA2308453 A1 CA 2308453A1 CA 002308453 A CA002308453 A CA 002308453A CA 2308453 A CA2308453 A CA 2308453A CA 2308453 A1 CA2308453 A1 CA 2308453A1
Authority
CA
Canada
Prior art keywords
antagonist
cocaine
food
sch
agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002308453A
Other languages
English (en)
French (fr)
Inventor
Vicki Coffin
Paul W. Glue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2308453A1 publication Critical patent/CA2308453A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA002308453A 1997-10-28 1998-10-26 Method of reducing craving in mammals Abandoned CA2308453A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US95921397A 1997-10-28 1997-10-28
US08/959,213 1997-10-28
PCT/US1998/022255 WO1999021540A2 (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals

Publications (1)

Publication Number Publication Date
CA2308453A1 true CA2308453A1 (en) 1999-05-06

Family

ID=25501785

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002308453A Abandoned CA2308453A1 (en) 1997-10-28 1998-10-26 Method of reducing craving in mammals

Country Status (16)

Country Link
EP (1) EP1043980A2 (pt)
JP (1) JP2001520989A (pt)
KR (1) KR20010031470A (pt)
CN (1) CN1283116A (pt)
AR (1) AR015984A1 (pt)
AU (1) AU1110099A (pt)
BR (1) BR9814830A (pt)
CA (1) CA2308453A1 (pt)
CO (1) CO4970824A1 (pt)
HU (1) HUP0100115A2 (pt)
IL (1) IL135659A0 (pt)
NO (1) NO20002149L (pt)
PE (1) PE122299A1 (pt)
SK (1) SK5812000A3 (pt)
WO (1) WO1999021540A2 (pt)
ZA (1) ZA989786B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6410527B1 (en) * 1998-03-02 2002-06-25 Schering Corporation Method of treating obsessive compulsive disorders, somatoform disorders, dissociative disorders, eating disorders, impulse control disorders, and autism
PE20000333A1 (es) * 1998-03-02 2000-05-13 Schering Corp Metodo para tratar desordenes compulsivos obsesivos, desordenes somatoformes, desordenes disociativos, desordenes al comer, desordenes de control de impulso y autismo
US6890951B2 (en) 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
US6541520B1 (en) 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
IL137937A0 (en) * 1999-08-27 2001-10-31 Pfizer Prod Inc A pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal
US6395783B1 (en) 2000-10-23 2002-05-28 Brookhaven Science Associates, Llc Treatment of PCP addiction and PCP addiction-related behavior
US6462084B1 (en) 2001-05-14 2002-10-08 Brookhaven Science Associates, Llc Treatment for obsessive-compulsive disorder (OCD) and OCD-related disorders using GVG
DE60231896D1 (de) 2001-11-05 2009-05-20 Krele Pharmaceuticals Llc Zusammensetzungen und verfahren zur erhöhung der compliance mit therapien unter verwendung von aldehyddehydrogenase-hemmern und zur behandlung von alkoholsmus
JP6355921B2 (ja) 2010-09-01 2018-07-11 トニックス ファーマスーティカルズ, インコーポレイテッドTONIX Pharmaceuticals, Inc. コカイン嗜癖の治療
AU2013289922B2 (en) 2012-07-12 2016-12-15 Psyadon Pharmaceuticals, Inc. Fused benzazepines for treatment of Tourette's Syndrome
SMT202000398T1 (it) * 2013-10-18 2020-09-10 Emalex Biosciences Inc Benzazepine fuse per il trattamento della balbuzie
CN110327350B (zh) * 2019-07-11 2021-02-23 温州医科大学 多巴胺d1受体拮抗剂sch39166在作为制备治疗眼部病理性血管新生药物的应用
CN110833621A (zh) * 2019-12-06 2020-02-25 中国医科大学 多巴胺受体1拮抗剂在制备治疗对氯胺酮致小鼠类精神分裂症药物上的应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5607967A (en) * 1994-10-27 1997-03-04 Merck & Co., Inc. Treatment of alzheimer's disease with 5-(tetradecyloxy)-2-furan carboxylic acid
AU3408097A (en) * 1996-06-06 1998-01-05 Ergo Research Corporation Treatment of lipid and glucose metabolism disorders with dopamine and seroto nin agonists

Also Published As

Publication number Publication date
WO1999021540B1 (en) 1999-10-28
SK5812000A3 (en) 2000-12-11
HUP0100115A2 (hu) 2001-06-28
JP2001520989A (ja) 2001-11-06
NO20002149L (no) 2000-06-26
AR015984A1 (es) 2001-05-30
WO1999021540A3 (en) 1999-09-02
AU1110099A (en) 1999-05-17
ZA989786B (en) 1999-04-28
NO20002149D0 (no) 2000-04-27
EP1043980A2 (en) 2000-10-18
PE122299A1 (es) 1999-12-04
CN1283116A (zh) 2001-02-07
IL135659A0 (en) 2001-05-20
KR20010031470A (ko) 2001-04-16
WO1999021540A2 (en) 1999-05-06
CO4970824A1 (es) 2000-11-07
BR9814830A (pt) 2000-10-03

Similar Documents

Publication Publication Date Title
US6262049B1 (en) Method of reducing nicotine and tobacco craving in mammals
Watkins et al. Blockade of nicotine self-administration with nicotinic antagonists in rats
Rose et al. Nicotine–mecamylamine treatment for smoking cessation: The role of pre-cessation therapy.
US8729070B2 (en) CNS pharmaceutical compositions and methods of use
Blomqvist et al. Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol
US9579299B2 (en) CNS pharmaceutical compositions and methods of use
CA2308453A1 (en) Method of reducing craving in mammals
WO2004091593A2 (en) Methods for the treatment of pain comprising opioid antagonists
SK13312000A3 (sk) Použitie kabergolínu pri liečbe syndrómu nepokojných nôh
KR101767273B1 (ko) 중독의 예방 및 치료용 조성물 및 방법
JP2003095979A (ja) ヒスタミンレセプターアンタゴニストの組み合わせを用いる上気道アレルギー性応答の処置
JP2001515475A (ja) 尿失禁、動揺病及びめまいの治療薬の製造のためのデスカルボエトキシロラタジンの使用
WO1995007690A1 (en) Composition and method for treating nicotine craving in smoking cessation
US20080194631A1 (en) Medicament For the Treatment of Central Nervous System Disorders
KR20060100443A (ko) 이상지혈증의 예방과 치료, 및 이상지혈증 및(또는) 비만과관련된 질환의 예방과 치료를 위한 약제의 제조에있어서의 피라졸 유도체의 용도
EP2138174A1 (en) Pharmaceutical composition in the form of a sublingual tablet consisting of a non-steroidal anti-inflammatory agent and an opiate analgesic for pain management
AU629688B2 (en) Slowly dissociating (tight binding) dopamine, serotonin or norepinephrine reuptake inhibitors as cocaine, amphetamine and phencyclidine antagonists
US20080280862A1 (en) Methods, compositions, and kits for the treatment of pain
Carroll et al. Effects of dopamine transporter selective 3-phenyltropane analogs on locomotor activity, drug discrimination, and cocaine self-administration after oral administration
WO2016027259A1 (en) Cns pharmaceutical compositions and methods of use
MXPA00004135A (en) Method of reducing craving in mammals
CZ20001387A3 (cs) Použití antagonisty a jeho sestava
PH12015500915B1 (en) Uses of bremelanotide in therapy for female sexual dysfunction
Glasser et al. Safety and efficacy of monotherapy with fantofarone, a novel calcium channel antagonist, in patients with chronic stable angina pectoris
WO2007145874A1 (en) Anti-nicotine treatment comprising use of three anticholinergic agents

Legal Events

Date Code Title Description
FZDE Discontinued